A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2011

Conditions

Advanced or Metastatic Solid TumorsCancerSolid Cancers

Interventions

DRUG

SF1126

Dose Escalating with 3+ patients in each cohort

Trial Locations (4)

Emory Winship Cancer Institute, Atlanta

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Scottsdale Clinical Research Institute, Scottsdale

Arizona Cancer Center, Tucson